Could a tiny HPV shot still protect? small study tests lower dose

NCT ID NCT04235257

Ongoing Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a smaller, one-fifth dose of the HPV vaccine, given into the skin instead of the muscle, can still trigger a good immune response in adults aged 27 to 45. Researchers are comparing two types of HPV vaccines in 40 volunteers in Seattle. The goal is to see if a lower dose could be a practical option for expanding vaccine access.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HPV vaccine (Gardasil 9 or bivalent HPV VLP vaccine), given as a one-fifth dose into the skin
What this could lead to: If successful, this could show that a smaller, cheaper dose of HPV vaccine is effective, potentially making vaccination more accessible for adults.
What could go wrong: This is a very small early-phase trial with only 40 participants, so results may not apply to the general population. The fractional dose might not produce a strong enough immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV INFECTION HPV VACCINE

Contacts and locations

Locations

University of Washington Virology Research Clinic

Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.